NVP 1705
Alternative Names: NVP-1705Latest Information Update: 22 Dec 2021
Price :
$50 *
At a glance
- Originator Navipharm
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 02 Dec 2021 Preclinical trials in Unspecified in South Korea (PO) before December 2021 (NCT05141110)
- 02 Dec 2021 Navipharm plans a pharmacokinetics phase I trial in Healthy volunteers in South Korea in December 2021 (NCT05141110)